Tandem Mobi Insulin Pump Correction, 3 Software Versions

Tandem Diabetes Care has issued an Urgent Medical Device Correction for Tandem Mobi insulin pumps running software versions 7.6.0.1, 7.6.0.3, and 7.7.0.1 due to false motor failure detection that can trigger Malfunction 12, stopping insulin delivery and terminating CGM communication. The FDA has classified this as a Class I recall—the most serious type—and reports four serious injuries as of November 4, 2025. Affected users must update to software version 7.9.0.2 immediately and contact Tandem at 1-877-801-6901 if Malfunction 12 occurs.

3-Year HKD Government Bond Tender Raises HK$0.75B at 2.331% Yield

The Hong Kong Monetary Authority, as representative of the HKSAR Government, announced results of a 3-year HKD institutional Government Bond tender through re-opening under the Infrastructure Bond Programme. A total of HK$0.75 billion in bonds were issued against HK$4.592 billion in applications, yielding a bid-to-cover ratio of 6.12. The average accepted price was 103.15, implying an annualised yield of 2.331%. Settlement is 23 April 2026 with maturity on 5 December 2029.

15-Year HKD Bonds Tender, HK$1.0B Offered, 4.46 Bid-Cover

The HKMA announced the results of a 15-year HKD Government Bond tender held on 22 April 2026 under the Infrastructure Bond Programme, reopening issue number 15GB3912001. A total of HK$1.0 billion in bonds were offered, attracting HK$4.460 billion in applications, producing a bid-to-cover ratio of 4.46. The bonds were allotted at an average price of 105.06, implying an annualised yield of 3.313%, with maturity set for 5 December 2039 and a coupon rate of 3.75%.

HKMA Announces Results of 7-Year HKD Institutional Government Bonds Tender

The Hong Kong Monetary Authority, acting as representative of the HKSAR Government, announced results of a 7-year HKD Institutional Government Bonds tender held on 22 April 2026 under the Infrastructure Bond Programme. HK$1.25 billion in bonds were offered and issued, while HK$7.655 billion in tender applications were received, yielding a bid-to-cover ratio of 6.12. The average price accepted was 101.68, implying an annualised yield of 2.656%, with settlement scheduled for 23 April 2026 and maturity on 7 February 2033.

Five HK Banks Flagged for Fraudulent Websites, Phishing Scams

The HKMA issued a public scam alert on 22 April 2026 warning consumers about fraudulent websites, internet banking login screens, and phishing emails impersonating five Hong Kong banks: The Bank of East Asia, Shanghai Commercial Bank, Chong Hing Bank, OCBC Bank (Hong Kong), and DBS Bank (Hong Kong). The alert advises that legitimate banks will not send SMS or emails containing embedded hyperlinks directing customers to banking websites for transactions, nor will they solicit sensitive information such as login passwords or one-time passwords by phone, email, or SMS. Consumers who may have disclosed personal information or conducted transactions through these scams are directed to contact the relevant bank and report the matter to the Hong Kong Police Force Crime Wing Information Centre at 2860 5012.

Northern Metropolis Financial Advisory Taskforce Established by HKMA and HKAB

The Hong Kong Monetary Authority (HKMA) and The Hong Kong Association of Banks (HKAB) jointly established the Northern Metropolis Financial Advisory Taskforce on 22 April 2026 to explore financing solutions supporting the development of the Northern Metropolis. The Taskforce comprises representatives from the HKMA, HKAB and 15 banks with experience in large-scale project financing, with the Chinese Banking Association of Hong Kong participating as an observer. The Taskforce will provide professional advice on financing and banking services, explore related financing needs, and facilitate expertise exchange to strengthen banking sector support for key Northern Metropolis projects.

RMB Bond Tender, 22 Apr, Issue Amount RMB5bn

The Hong Kong Monetary Authority published the results of four RMB Sovereign Bond tenders conducted on 22 April 2026, with total issuance of RMB 15.5 billion across four maturities: 2-year (RMB 5,000 million, coupon 1.38%), 3-year (RMB 5,000 million, coupon 1.40%), 5-year (RMB 4,500 million, coupon 1.57%), and 15-year (RMB 1,000 million, average accepted coupon rate 2.05%). The Ministry of Finance of the People's Republic of China is the issuer, with settlement date of 24 April 2026.

$102,000 Grant for Tribal Education, Closes Jun 8

The National Institute of Food and Agriculture (NIFA) has posted a $4,000,000 funding opportunity for the Federally Recognized Tribes Extension Program (FRTEP), with a minimum award of $102,000 per grant and up to 37 expected awards. Eligible applicants include 1862, 1890, and 1994 Land-grant Colleges and Universities, which may subcontract to other organizations as necessary for project conduct. Applications close June 8, 2026.

FY24 CRISI-CDS San Diego At-grade Crossing Elimination Study Grant, $500,000

The Federal Railroad Administration (FRA) has posted a $500,000 CRISI Congressionally Directed Spending grant opportunity for the San Diego At-grade Crossing Elimination Study (SD ACES). Only the San Diego Association of Governments (SANDAG) is eligible to apply. The grant funds early-action safety planning to analyze potential grade separations and alternative alignments at eleven at-grade rail crossings within a major transportation corridor in and near downtown San Diego. Applications close May 8, 2026.

NEH Landmarks of American History Institutes: Up to $230,000 for K-12 Teacher Professional Development

The National Endowment for the Humanities (NEH) Division of Lifelong Learning has posted a Notice of Funding Opportunity (NOFO) for the Landmarks of American History and Culture and Summer Institutes program, offering awards up to $230,000 per grant. The program supports humanities education through professional development for K-12 teachers and higher education faculty. Total program funding stands at $7,000,000 with an expected 30 awards. Applications are due June 25, 2026, with a funding opportunity identifier of 20260625-EDK-EDU.

Rural Health and Safety Education Competitive Grants Program, $350,000 Award

USDA NIFA has posted a Notice of Funding Opportunity for the Rural Health and Safety Education Competitive Grants Program (ALN 10.516), offering up to $3,000,000 in total program funding with individual awards ranging from $350,000 to $350,000. Applications are accepted from 1862 and 1890 Land-grant Colleges and Universities, including Central State University, Tuskegee University, and West Virginia State University, as well as Tribal Colleges and Universities designated as 1994 Land-grant Institutions. The program closes June 23, 2026, and requires no cost-sharing or matching funds.

AEIF Freedom 250 Grant $5K–$35K for US-ROC Public Diplomacy

The U.S. Department of State's Embassy Brazzaville announces an open competition for the AEIF (American Emerging Innovation Forum) program celebrating the Freedom 250 milestone, promoting American innovation, technology, and the 2026 World Cup hosted in the United States, while fostering stronger commercial ties between the U.S. and Republic of the Congo. Awards range from $5,000 to $35,000, with applications closing May 22, 2026. Eligible applicants include exchange alumni from U.S. government-funded or sponsored exchange programs, as well as not-for-profit organizations and educational institutions that partner with such alumni.

BJA FY25 Emergency Federal Law Enforcement Assistance Grant, $60,755 Minimum, Closes Apr 30

The Bureau of Justice Assistance (BJA) posted FY25 Emergency Federal Law Enforcement Assistance (EFLEA) Program funding opportunity O-BJA-2025-172567 on Grants.gov, offering a minimum award of $60,755 for emergency situations where state and local resources are inadequate to protect lives and property or enforce criminal law. Eligible applicants are limited to state governments. The opportunity closes April 30, 2026, and applications must be submitted through www.grants.gov.

2026 Alumni Engagement Innovation Fund, Bosnia and Herzegovina, $5k-$35k

The U.S. Mission to Bosnia and Herzegovina Public Diplomacy Section announces the 2026 Alumni Engagement Innovation Fund (AEIF), offering $5,000 to $35,000 for U.S. government-sponsored exchange program alumni to develop and implement projects promoting shared interests and policy objectives while celebrating Freedom 250. Eligible applicants include alumni teams with at least two exchange program alumni, with one designated team lead, and the opportunity closes April 30, 2026.

U.S. Mission New Zealand Public Diplomacy Annual Program Statement, $10k-$100k Awards

The U.S. Department of State's Mission New Zealand Public Diplomacy Section announces an open competition for grants to advance U.S.-New Zealand economic, scientific, and cultural ties. The program offers $350,000 in total funding for 7 expected awards ranging from $10,000 to $100,000 per award. Applications closing July 15, 2026 may address science cooperation, prosperity and innovation, or democratic and cultural programming.

Public Diplomacy Grants, Cook Islands & Niue, $10k-$50k

The U.S. Department of State's U.S. Mission New Zealand announces an open competition for public diplomacy grants to advance U.S.-Cook Islands and U.S.-Niue maritime cooperation, economic and cultural ties. Five awards of $10,000 to $50,000 each will be made under Assistance Listings 19.040, with applications closing July 15, 2026. Eligible applicants include nonprofits and institutions of higher education.

Tribal Colleges Research Grants, $150k-$2.5M, Due Dec 31

NIFA announces the Tribal Colleges Research Grants Program (TCRGP) for fiscal year 2026, with $11,574,000 in total program funding and 15 expected awards ranging from $150,000 to $2,500,000. Applications close December 31, 2026, and are restricted to the 35 designated 1994 land-grant institutions listed in the NOFO. Priority areas include innovative agricultural technologies such as AI, data science, robotics, and digital tools, with emphasis on training undergraduate students in these fields.

SIC Colombia Consumer Protection and Competition News April 2026

SIC Colombia publishes its April 2026 consumer protection and competition news summary, covering enforcement actions through April 20. The most significant action is sanctions exceeding $1.379 billion COP against a pharmaceutical laboratory and wholesale distributor for price-control violations with markups of 46% and 400%. The regulator also initiated investigations against telecom operators Claro and Movistar for unauthorized equipment charges, opened consumer protection probes into e-commerce platforms D1 and RAPPI, and issued information requests to telecommunications market agents regarding competitive conditions.

True Footage Inc v Automax AI Inc - Copyright

True Footage Inc. filed a civil copyright complaint against defendants Humza Ahmed, Automax AI Inc., and Automax AI (US) Inc. in the Northern District of California on April 22, 2026. The complaint was filed with the court accompanied by three exhibits and required a $405 filing fee. This marks the initiation of a federal civil action alleging copyright infringement.

NY Executive Order 60 Prohibits State Employees from Insider Trading in Prediction Markets

Governor Kathy Hochul has issued Executive Order 60 prohibiting state employees serving at the pleasure of the Governor and public authority members appointed by the Governor from using nonpublic information obtained in their official duties to profit or avoid loss from participation in prediction markets or similar services. The order covers exchange-traded platforms not licensed by the New York State Gaming Commission, including contracts contingent on elections, sporting events, individual actions or speech, and economic indicators. Violations may result in dismissal, other sanctions, or referral to law enforcement or the Commission on Ethics and Lobbying in Government.

Qu Biologics Inc. EP3137108A1 Anti-Microbial Immunomodulation

The European Patent Office published EP3137108A1 on April 15, 2026, titled 'ANTI-MICROBIAL IMMUNOMODULATION.' The patent application, filed by Qu Biologics Inc., names inventors Harold David Gunn, Salim Dhanji, and David W. Mullins. The invention is classified under IPC categories A61K 39/108, A61K 39/00, A61P 31/04, and A61P 31/12. Designation extends across all relevant European member states including DE, FR, GB, IT, NL, ES, PL, and 24 others.

Compositions for Treating Bone Diseases and Broken Bones, Brigham Young University, EP2755661A1

The EPO published patent application EP2755661A1 for Brigham Young University on April 15, 2026, covering compositions for treating bone diseases and broken bones. The application, classified under A61K 31/575 and related pharmaceutical classes, designates 35 European states including AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, HR, HU, IE, IT, LI, LT, LU, MC, NL, NO, PL, PT, RO, SE, SI, SK, and SM. Inventors are Carl Genberg and Paul B. Savage.

LEO Pharma A/S Pharmaceutical Spray Composition Patent EP2859886A1

The European Patent Office published patent application EP2859886A1 for LEO Pharma A/S covering a pharmaceutical spray composition. The application lists five inventors: Lind, Marianne; Rasmussen, Grit; Sonne, Mette Rydahl; Hansen, Jens; and Petersson, Karsten. The IPC classifications span A61K 9/12 (aerosol compositions), A61K 47/06 (organic compounds), A61K 47/10 (glycols), and A61K 9/00 (pharmaceutical preparations). The application designates 37 European states including major pharmaceutical markets such as Germany, France, the United Kingdom, and the Netherlands.

AbbVie Inc. - Methods for Treating HCV (EP3125889A1)

AbbVie Inc. filed European patent application EP3125889A1 for methods of treating Hepatitis C Virus (HCV) infection with pharmaceutical compositions classified under A61K 31/454, A61K 31/498, and A61K 31/7072. The European Patent Office published the application on April 15, 2026, establishing a priority date of October 16, 2015. The patent designates all European Patent Convention contracting states, covering AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Agios Crystalline Salt Forms of Quinolinesulfonamide - EP3972957A1

The European Patent Office published application EP3972957A1 on 15 April 2026, covering crystalline salt forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide. Agios Pharmaceuticals, Inc. is the applicant, with Lisa M. Grove listed as inventor. The application covers the pharmaceutical compound classified under C07D 215/36, A61P 7/06, and A61K 31/4709, with designated states spanning across European member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Redwood Bioscience Anti-HER2 Antibody-Maytansine Conjugate Patent Application EP3151830A1

The EPO published patent application EP3151830A1 by Redwood Bioscience, Inc. on April 15, 2026, covering anti-HER2 antibody-maytansine conjugates and methods of use for cancer treatment. The application names eight inventors and falls under IPC classifications A61K 47/68 and A61K 31/4045, with potential coverage across 34 European designated states including Germany, France, the United Kingdom, Italy, and Spain.

Daicel Corporation Osteoclast Differentiation Inhibitor Urolithin EP3756664A1

The European Patent Office published patent application EP3756664A1 for Daicel Corporation on April 15, 2026, covering osteoclast differentiation inhibitor compositions containing urolithin. The inventors are KOBATA Kenji, NAKATANI Sachie, and KUDOH Masatake. The application is classified under A61K 31/37 (phthalide compounds) with designations covering 32 European states including DE, FR, GB, IT, and NL.

Selective Reduction of Cysteine Residues in IL-17 Antibodies

The European Patent Office published patent application EP3237445A1 by Novartis AG, covering methods for the selective reduction of cysteine residues in IL-17 antibodies. The application names HEITZMANN, Markus and WINKLER, Johann as inventors, with international patent classification codes C07K 16/24 and A61K 39/395. This A1 publication includes the European search report and designates all EU member states plus Switzerland, Norway, and other European Economic Area countries.

Genentech Patent - Quaternary Amine ADC Compounds, Apr 2026

The EPO published patent application EP3226909A1 for Genentech, Inc., covering quaternary amine compounds and antibody-drug conjugates (ADCs) thereof. The application, filed under IPC classifications A61K 47/68, A61P 35/00, and multiple C07D chemical classes, designates all current EPO contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR. Named inventors are John A. FLYGARE, Thomas PILLOW, and Leanna STABEN.

Strike Bio RNAi Cancer Treatment Patent Application EP3134528A1

The European Patent Office published patent application EP3134528A1 titled 'Multiple Targeted RNAi for the Treatment of Cancers' on April 15, 2026. The applicants are Strike Bio, Inc. and Baylor College of Medicine, both based in the United States. The invention covers RNAi-based therapeutics targeting multiple genes for cancer treatment, with the application designating 34 European member states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Porous Particles Patent, Lucideon Limited, Apr 2026

The EPO published patent application EP3236946A1 for porous particles by Lucideon Limited on April 15, 2026. The inventors are Philip Richard Jackson, Mark Cresswell, and Ian F. Campbell, with the application classified under pharmaceutical formulation codes A61K 9/14, A61K 9/16, A61K 9/20, and A61K 31/00. The patent designation extends across all European Patent Convention contracting states including Germany, France, the United Kingdom, Italy, Spain, and 25 others. Pharmaceutical manufacturers developing similar porous particle formulations should evaluate freedom-to-operate implications within the designated states.

I-59 and U.S. 49 Ramp Closures, Forrest County, April 27-28

MDOT has issued a traffic advisory for temporary ramp closures at the U.S. 49 N ramp to I-59 N and the I-59 S ramp to U.S. 49 N in Forrest County. The closures are scheduled for Monday, April 27 and Tuesday, April 28, 2026, from 6:00 a.m. to 4:30 p.m. each day. The work is associated with an ongoing interstate resurfacing project, and motorists are advised to seek alternate routes and remain alert for roadside workers.

I-55 Lane and Ramp Closures Madison County April 22-23

MDOT announces temporary lane and ramp closures on I-55 southbound between Steed Rd. and I-220 in Madison County, Mississippi, from 9 p.m. Wednesday, April 22 until 6 a.m. Thursday, April 23 for overhead sign replacement. The Old Agency Rd. ramps to I-55 south and the Natchez Trace Parkway ramp to I-55 south will be temporarily closed. Motorists seeking southbound I-55 access should use I-55 north to Colony Park Blvd. or seek alternate routes.

MDOT Litter Cleanup Spring 2026 Mississippi Highways

MDOT announced its annual spring litter prevention and cleanup campaign along Mississippi state highways this April, coinciding with Earth Day (April 22) and Keep America Beautiful Month. The agency is hosting Trash Bash events across multiple Mississippi districts through late April 2026 in partnership with Keep Mississippi Beautiful as part of the national Great American Cleanup campaign, which has run annually since 1989. MDOT employees are volunteering to remove thousands of bags of trash from highly visible roadside areas and conducting litter prevention education at schools and communities statewide.

Old Byram Rd Bridge Closure, May 11 to June 22

MDOT has issued an updated traffic advisory for a temporary bridge closure on Old Byram Rd. over I-55 in Hinds County. The closure begins at 7 a.m. on Monday, May 11 and runs through Monday, June 22, 2026. Drivers should seek alternate routes during the closure and can stay updated via MDOTtraffic.com, the MDOT Traffic mobile app, or by following @MississippiDOT on Facebook and X.

Influence of Genetic Polymorphism on Dose-Dependent Analgesic Response and Safety to Propofol in General Anesthesia

This ClinicalTrials.gov entry registers a new observational study (NCT07543523) investigating how genetic polymorphisms in drug-metabolizing enzymes — CYP2B6, CYP2C9, and UGT1A9 — affect individual patient response to propofol, a widely used intravenous anesthetic. The study will enroll patients undergoing general anesthesia and assess outcomes including induction time, recovery time, and adverse-effect profiles across poor and altered metabolizer phenotypes. Study interventions include Propofol Group and Isoflurane Group assignments, with conditions focused on analgesia.

Phase 2 Brenipatide (LY3537031) Trial for IBS-D, Apr 2026

NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07545759) evaluating subcutaneously administered brenipatide (LY3537031) against placebo in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study will assess tolerability, safety, and efficacy over approximately 35 weeks. No regulatory approval, efficacy finding, or compliance obligation is established by this registry entry.

Determines Effect of Virtual Glasses on Pain and Anxiety During IUD Application

A randomized controlled experimental study registered on ClinicalTrials.gov (NCT07545850) investigates whether using virtual reality glasses during intrauterine device (IUD) application affects pain and anxiety levels in women. The study, registered as of April 22, 2026, tests two hypotheses: that VR during IUD insertion impacts pain levels (H1-a) and anxiety levels (H1-b). This is an observational healthcare research entry documenting study parameters rather than a regulatory action.

Phase 1b aKLmRNA Trial for Aging, 21 Subjects

A Phase 1b randomized, double-blind, placebo-controlled clinical trial (NCT07544420) evaluating aKLmRNA (AKL003), a novel mRNA-mediated protein replacement therapy formulated in lipid nanoparticles, will enroll approximately 21 subjects with the condition of aging. Subjects will be randomized in a 2:1 ratio (active treatment:placebo), with each receiving two injections of 0.5 mg aKLmRNA or saline placebo. The study is registered on ClinicalTrials.gov as a Phase 1 trial with an April 22, 2026 posting date.

Phase 1 DISP-10 Trial for Advanced GI Cancers

NIH registered a Phase 1 multicenter open-label study (NCT07544589) evaluating DISP-10, a combination therapy of DV-10 adenovirus and idecabtagene vicleucel (BCMA-directed CAR-T), in adult participants with advanced gastrointestinal cancers including colorectal, gastric, esophageal, and gastroesophageal adenocarcinoma. The trial consists of dose-escalation (Part 1) to establish a recommended dose for expansion, followed by dose-expansion (Part 2) to evaluate safety and efficacy at that dose.

Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study

This study registers a prospective longitudinal investigation examining fatigue predictors in patients diagnosed with Sjögren's disease over a 3-month period at Kahramanmaras Sutcu Imam University Medical Faculty Hospital. The study will collect demographic and clinical data including laboratory results, pressure pain threshold measurements using a digital algometer, and validated questionnaires assessing fatigue, disease activity, symptoms, anxiety, depression, pain catastrophizing, sleep quality, and physical activity at baseline and 3-month follow-up. This clinical trial registration does not create compliance obligations for regulated entities — it is an informational record of planned research.

Observational HPV Testing Study Before Subtotal Hysterectomy

Clinical trial NCT07545525 is an observational study registered on April 22, 2026, evaluating high-risk HPV testing in patients indicated for subtotal hysterectomy. Patients testing HPV-positive will proceed to expert colposcopy and conisation if clinically indicated at the time of hysterectomy. The study screens for cervical cancer and human papilloma virus as co-occurring conditions.

Radiologist-Integrated Finite Element Framework for Acromial Stress in Reverse Shoulder Arthroplasty (NCT07545707)

NCT07545707 is a prospective single-center observational study registered April 22, 2026, examining an approach using high-resolution CT and MRI scans combined with customized finite element modelling to analyze stress on the acromion of patients who have undergone reverse shoulder arthroplasty (RSA) surgery. The study will assess rotator cuff deficiency using Goutallier classification quantified as Cuff Deficiency Index (CDI) to calculate deltoid forces for finite element analysis. Von Mises stresses in specific acromion zones defined by Levy et al. will then be analyzed. The study focuses on patients with Rotator Cuff Injuries and Shoulder Fractures.

Effects of Cistanche Deserticola Supplementation on Anaerobic Exercise Performance and Recovery in Men

A double-blind, randomized, placebo-controlled clinical trial has been registered to evaluate whether 8 weeks of Cistanche deserticola supplementation combined with standardized anaerobic training improves exercise performance, recovery markers, and body composition in young adult men across different athletic training levels. Participants will be assigned to receive either Cistanche deserticola extract or matched placebo while completing the same supervised training protocol, with outcomes assessed via Wingate tests, jump performance, blood lactate, creatine kinase, and hormonal indicators.

CAA 2026 Provider-Based Clinic Compliance, Attestations, Medicare Reimbursement

K&L Gates LLP attorneys Limo Cherian, Andrew Ruskin, and Sarah Staples-Carlton analyze the Consolidated Appropriations Act of 2026 and its implications for provider-based departments. The article explains provider-based status, mandatory attestation requirements, and compliance steps hospitals and health systems must take to protect Medicare reimbursement. The episode provides practical guidance on navigating the new regulatory landscape for provider-based clinics.

LDH Confirms First Measles Case in Louisiana for 2026

The Louisiana Department of Health confirmed one case of measles in a pediatric resident of Region 1 (Jefferson, Orleans, Plaquemines, and St. Bernard parishes) on April 22, 2026. The patient, who was partially vaccinated and exposed during international travel, is in isolation and receiving treatment at a Region 1 hospital. Public exposures occurred at two Kenner retail locations on April 17. This is the first measles case reported in Louisiana in 2026, following three cases in 2025.

NCUA Proposes Amending Credit Union-to-Bank Merger Regulations

The NCUA Board is proposing to amend 12 CFR part 708a, subpart C to streamline merger requirements for insured credit unions converting to banks. The proposal would eliminate the definition of "clear and conspicuous" formatting requirements (currently mandating bold type and minimum 12-point font), remove the requirement to publish pre-board-vote notice in a general circulation newspaper in favor of a member home banking landing page notice, and revise due diligence reporting requirements for merger partner location and negotiation description. The Board is accepting public comments through June 22, 2026. Credit unions considering bank mergers and financial institutions advising on such transactions should monitor this rulemaking, as it could materially alter the procedural and disclosure landscape for charter conversions.

Meeting Registration List, EERE-2023-BT-STD-0005, posted 22nd Apr

EERE posted a meeting registration list for proceeding EERE-2023-BT-STD-0005 on April 22. This document identifies participants registered to attend a meeting related to building technology and efficiency standards. The registration list is an administrative record-keeping document with no compliance obligations or regulatory changes.

Miguel Vega v. Commissioner of Correction — Brady Disclosure

The Connecticut Supreme Court in Miguel Vega v. Commissioner of Correction affirmed the Appellate Court's judgment on an alternative basis, holding that while a prosecutor's duty under Brady extends to exculpatory information known to other prosecutors in the same state's attorney's office, the failure to disclose a witness's prior false testimony was immaterial because there was no reasonable probability it would have changed the outcome of Vega's murder trial. The court reversed the Appellate Court's rationale that the prosecutor had no responsibility to search unrelated case files absent a specific defense request. Argued October 29, 2025—officially released April 21, 2026.

State v. Lang — Rehearing Request Not Considered

The Louisiana Court of Appeal, First Circuit declined to consider Isiah Lang's application for rehearing, citing the court's denial of the original writ application as the basis for non-consideration. The ruling invokes Uniform Rules of Louisiana Courts of Appeal, Rules 2-18.1 and 2-18.7, which govern when rehearing applications may be entertained. The matter originated in the 19th Judicial District Court, Parish of East Baton Rouge, under docket DC-24-02369.